CLSA Challenges the U.S. Congress’ H.R. 3 in Support of California Biotech, Patients, and Innovation

The California Life Sciences Association (CLSA) has been very active in the current discussions on Medicare Pricing Reform, and finds itself at the center of the debate with the US congress regarding the announced plans to introduce international reference pricing for medicines. CLSA is a 1000-member trade association representing California’s life sciences industry and was founded in 2015 when the Bay Area Bioscience Association (BayBio) and the California Healthcare Institute (CHI) merged.

We’re joined in this podcast by two CLSA representatives, Bill Newell, the CEO of Sutro Biopharma and the former CLSA board chair, and Jenny Nieto, CLSA’s Vice President of Federal Government Relations & Alliance Development, who leads the organizations policy activities in DC.

See omnystudio.com/listener for privacy information.